Chronoscale Holdings Corp quarterly report, Q1 FY2015

Ekso Bionics Holdings, Inc. — Form 10-Q Summary

Business context and reporting period

The filing is for the three months ended March 31, 2015. Although the request metadata names Chronoscale Holdings Corp, the registrant identified in the filing is Ekso Bionics Holdings, Inc. Ekso develops and sells wearable robotic exoskeletons and provides engineering services, including government-funded research.

Financial performance and position

Amounts below are in millions of dollars unless stated otherwise.

MetricQ1 2015Q1 2014 or prior period
Medical device revenue$0.985$0.527
Engineering services revenue$0.704$0.535
Total revenue$1.689$1.062
Gross profit / margin$0.403 / 24%$0.480 / 45%
Operating expenses$4.496$4.371
Operating loss($4.093)($3.891)
Net loss($4.115)($81.766)
Net loss per share($0.04)($1.22)
Cash used in operations$3.828$5.459

At March 31, 2015, cash was $21.133 million, down from $25.190 million at December 31, 2014. Total assets were $30.033 million and total liabilities were $10.936 million; stockholders’ equity was $19.097 million. Current assets were $25.550 million against current liabilities of $6.708 million. Notes payable totaled approximately $0.107 million; the company also disclosed $0.814 million of future operating lease payments. Cash flows included $0.281 million of investing outflows and $0.052 million of financing inflows.

Material changes versus the prior comparable period

  • Revenue increased 59%, driven by an 87% increase in medical device revenue and a 32% increase in engineering services revenue.
  • Gross profit declined despite revenue growth: cost of revenue rose 121%, and gross margin fell to 24% from 45%. Management attributed weaker medical-device margins primarily to service expenses associated with technology improvements to the device fleet.
  • Operating expenses increased 3%; higher sales and marketing and R&D costs were partly offset by lower general and administrative expenses.
  • The much smaller net loss compared with Q1 2014 chiefly reflects the absence of the prior-year $77.437 million non-cash warrant-liability loss. The warrants were amended in November 2014 and thereafter qualified for equity treatment. Operating loss, by contrast, widened.
  • Operating cash use improved year over year, but cash fell by $4.057 million during Q1 2015.

Outlook, risks, contingencies, and unusual items

  • Management estimated that available resources would fund obligations into the second quarter of 2016, based on current cash use and assumptions including revenue and gross-profit growth, modest incremental operating expenses, and possible increased rental activity. This is not a guarantee; the company said it expects to need significant additional financing within three to four quarters and may need to reduce spending or curtail operations if financing is unavailable.
  • Planned investment areas include clinical, sales and marketing initiatives; development and commercialization of a home-use device; and industrial exoskeletons.
  • The FDA had reclassified powered exoskeletons as Class II and requested 510(k) clearance for the Ekso GT. The company’s submission, filed December 24, 2014, was under review. Ekso continued marketing under its existing Class I registration, but warned that the FDA could require it to stop marketing or recall products and could impose penalties.
  • Disclosure controls and procedures were assessed as ineffective at March 31, 2015. Management said previously identified control deficiencies were considered remediated at year-end, but the revised controls had not operated long enough to establish effectiveness.
  • The company reported recurring losses and negative operating cash flows since inception, with an accumulated deficit of $75.916 million. Other stated risks include adoption and sales execution, competition, long sales cycles, regulation and reimbursement, intellectual property, financing availability, and stock volatility.
  • Management said there were no legal proceedings expected to have a material adverse effect. License agreements require royalties, including minimum annual royalties of $50,000 for 2015 and later years, and 1% of applicable net product sales.

Important facts for investors to verify

  • Confirm the registrant identity: the supplied filing names Ekso Bionics Holdings, Inc., not Chronoscale Holdings Corp.
  • Track FDA review and any conditions affecting continued marketing of the Ekso GT.
  • Assess whether revenue growth can translate into improved gross margins and lower operating cash use.
  • Verify financing plans, cash runway assumptions, and the availability and terms of future capital.
  • Monitor whether disclosure controls are tested and found effective after operating for a sufficient period.
  • Review the impact of customer concentration, lease and royalty commitments, and the company’s significant outstanding options and warrants.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.